12 November 2018 - A medicine used to treat a rare cancer which occurs predominantly in very young children has been accepted by the SMC for routine use in NHSScotland.

Dinutuximab beta (Qarziba) is used to treat neuroblastoma, a cancer of the nerve cells that is predominantly diagnosed in young children and has a high rate of mortality.

The committee was unable to accept atezolizumab (Tecentriq) for bladder cancer in patients who have already undergone chemotherapy. 

Also not recommended was fampridine (Fampyra) for the improvement of walking in adults with multiple sclerosis and walking disability.

Read SMC press release